logo-loader

Open Orphan hVIVO arm lands three new contracts

Published: 16:45 07 Jul 2020 AEST

Open Orphan PLC -

Open Orphan PLC (LON:ORPH) said its hVIVO lab services operation has signed three new contracts, adding to the momentum behind the business.

It has landed work with NoBACZ, a spin-out from the University of Cambridge, a new second deal with Nearmedic, and has agreed to run testing for an unnamed Cambridge, Massachusetts biotech.

"We are now continuing to sign additional new virology services contracts with third-party customers,” said Open Orphan chairman Cathal Friel in a statement.

“As such, this is delivering upon one of our key commitments from when we acquired hVIVO earlier this year that, as part of our growth strategy, we were going to expand the range of our service offerings to third party pharmaceutical and biotech companies,“ he added.

NoBACZ is developing an environmentally friendly antimicrobial, antiviral coating that prevents surfaces from being a major source of infection transmission.

It is working with hVIVO at its East London lab to test its products against a range of viruses, including coronaviruses.

It has won a second contract with Nearmedic, this time to support the development of a RegG3 drug as a treatment for COVID-19. This will be followed by the expansion of this product into disease areas such as cystic fibrosis.

Finally, it has inked an agreement to run in vitro testing from its laboratory for the unnamed US biotech company.

Open Orphan first half: 'period of integration, restructuring and setting...

Proactive Analyst Emma Ulker talks through how Open Orphan (LON:ORPH) performed in the first half of the year.  In the six-month period to June 2020, the company focused on integration and restructuring following its acquisition of lab services and challenge studies specialist hVIVO in...

on 30/9/20